Kestrel Therapeutics
Boston, US · Founded 2020 · Delaware corporation · 1 known investors
Biotech
Founders & leadership
FG
Frank G. HaluskaExecutive
Board
OK
Omar KhalilBoard director
NS
Nicholas SaccomanoBoard director
BS
Barbara SosnowskiBoard director
AP
Andrew PhillipsBoard director
DP
Denis PatrickBoard director
Investors · 1
Reported raises · per SEC filings
Form D private placements$20.7M disclosed across 4 rounds · 2021–2025
▶$5MraisedAug 2025 · 6 investors · BiotechnologyRule 506(b)
▶$5MraisedAug 2025 · 6 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Nicholas SaccomanoDirector
- Denis PatrickDirector
- Barbara SosnowskiDirector
- Omar KhalilDirector
- Andrew PhillipsDirector
- Frank G. HaluskaExecutive Officer, Director
- Offering amount
- $10M
- Amount sold
- $5M
- First sale
- Jul 2025
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
▶$8MraisedFeb 2025 · 7 investors · BiotechnologyRule 506(b)
▶$8MraisedFeb 2025 · 7 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Nicholas SaccomanoDirector
- Barbara SosnowskiDirector
- Frank G. HaluskaExecutive Officer, Director
- Omar KhalilDirector
- Andrew PhillipsDirector
- Denis PatrickDirector
- Offering amount
- $16M
- Amount sold
- $8M
- First sale
- Feb 2025
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
▶$7.5MraisedJan 2022 · 6 investors · BiotechnologyRule 506(b)
▶$7.5MraisedJan 2022 · 6 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Denis PatrickDirector
- Andrew PhillipsDirector
- Omar KhalilDirector
- Frank G. HaluskaExecutive Officer, Director
- Offering amount
- $40M
- Amount sold
- $7.5M
- First sale
- Dec 2021
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
▶$228KraisedMar 2021 · 4 investors · BiotechnologyRule 506(b)
▶$228KraisedMar 2021 · 4 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Frank G. HaluskaExecutive Officer, Director
- Offering amount
- $2M
- Amount sold
- $228K
- First sale
- Mar 2021
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- Who are Kestrel Therapeutics's investors?
- Kestrel Therapeutics's investors include Pfizer Venture Investments.
- How much funding has Kestrel Therapeutics raised?
- Kestrel Therapeutics has disclosed $20.7M raised across 4 rounds.
- Where is Kestrel Therapeutics headquartered?
- Kestrel Therapeutics is headquartered in Boston, US.